Loading...

PE anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_53-6dot7_PE_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_53-6dot7_PE_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_53-67_PE_CD8a_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD8a (clone 53-6.7) PE (solid line) or rat IgG2a, κ PE isotype control (dashed line).
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
100707 50 µg 30€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100708 200 µg 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References

(PubMed link indicates BioLegend citation)
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  2. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  3. Xu C, et al. 2017. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2017.05.071. PubMed
  4. He Y, et al. 2022. Adv Healthc Mater. 11:e2200905. PubMed
  5. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  6. Shi X, et al. 2022. Proc Natl Acad Sci U S A. 119:e2208506119. PubMed
  7. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  8. Chen Y, et al. 2022. Am J Cancer Res. 12:5286. PubMed
  9. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  10. Swan SL, et al. 2023. Front Immunol. 14:1085547. PubMed
  11. Wang F, et al. 2023. Int J Mol Sci. 24:. PubMed
  12. Tan J, et al. 2023. Acta Pharm Sin B. 13:632. PubMed
  13. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  14. Wu Y, et al. 2023. Nat Cancer. 4:382. PubMed
  15. Dang YZ, et al. 2023. Neoplasma. 70:123. PubMed
  16. Tang C, et al. 2023. Nat Commun. 14:1493. PubMed
  17. Hao H, et al. 2023. Nat Biomed Eng. . PubMed
  18. Tao Q, et al. 2023. Microbiol Spectr. :e0522922. PubMed
  19. Fukuzaki Y, et al. 2023. iScience. 26:106340. PubMed
  20. del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed
  21. Liu H, et al. 2023. Breast Cancer Res. 25:43. PubMed
  22. Fu S, et al. 2023. Nat Commun. 14:2248. PubMed
  23. Qin T, et al. 2023. Virol J. 20:75. PubMed
  24. Li T, et al. 2023. Nat Commun. 14:2498. PubMed
  25. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  26. Ye S, et al. 2023. Front Oncol. 13:1202750. PubMed
  27. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  28. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  29. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  30. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  31. Zveik O, et al. 2022. Glia. 70:1191. PubMed
  32. Liu H, et al. 2022. Cancer Immunol Res. 10:1028. PubMed
  33. Silva Pereira S, et al. 2022. Elife. 11: . PubMed
  34. del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed
  35. Lin G, et al. 2022. Int J Immunopathol Pharmacol. 36:3946320221117933. PubMed
  36. Zheng D, et al. 2023. Bioact Mater. 22:567. PubMed
  37. Wang H, et al. 2022. J Nanobiotechnology. 20:513. PubMed
  38. He Y, et al. 2022. Front Immunol. 13:986202. PubMed
  39. Hao J, et al. 2022. Cell Rep. 41:111804. PubMed
  40. Shi C, et al. 2023. Nat Nanotechnol. 18:86. PubMed
  41. Horkova V, et al. 2023. Nat Immunol. 24:174. PubMed
  42. An HW, et al. 2022. Cell Rep. 41:111878. PubMed
  43. Kumpunya S, et al. 2023. Front Immunol. 13:1010764. PubMed
  44. Huseni MA, et al. 2023. Cell Rep Med. 4:100878. PubMed
  45. Glaubitz J, et al. 2023. Gut. :. PubMed
  46. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  47. Lu T, et al. 2023. Cancer Immunol Immunother. :. PubMed
  48. Takacs GP, et al. 2023. Front Immunol. 13:993444. PubMed
  49. Pan C, et al. 2022. Cell Mol Immunol. 19:516. PubMed
  50. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  51. Li Z, et al. 2022. Nat Commun. 13:1845. PubMed
  52. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  53. Chen X, et al. 2009. Hum Immunol. 70:79. PubMed
  54. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  55. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
  56. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  57. Wu SY, et al. 2022. Mol Cancer. 21:84. PubMed
  58. Lee S, et al. 2021. JCI Insight. 6:. PubMed
  59. Manukian G, et al. 2021. Int J Radiat Oncol Biol Phys. 110:1341. PubMed
  60. Aguilera T, et al. 2016. Nat Commun. 7:13898. PubMed
  61. Hu HJ, et al. 2020. Cell Death Dis. 1.168055556. PubMed
  62. Yu K, et al. 2021. Cell Reports. 35(12):109273. PubMed
  63. Kagoya Y, et al. 2018. Nat Commun. 9:1915. PubMed
  64. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  65. Du Q, et al. 2019. Front Microbiol. 10:2050. PubMed
  66. Huang X, et al. 2019. Cancer Immunol Res. 1.388888889. PubMed
  67. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  68. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  69. Sng XYX, et al. 2020. J Immunol. 204:3108. PubMed
  70. Zhang S, et al. 2022. Cell Death Dis. 13:844. PubMed
  71. Plumlee CR, et al. 2020. Cell Host Microbe. 29(1):68-82.e5. PubMed
  72. Wong J, et al. 2015. Elife. 3: 07839. PubMed
  73. Ibrahim M, et al. 2016. J Evid Based Complementary Altern Med. 21: 171 - 176. PubMed
  74. He Y, et al. 2020. Sci Adv. 6:eaba7589. PubMed
  75. Zhao B, et al. 2020. Nat Commun. 11:908. PubMed
  76. van Erp EA, et al. 2019. Viruses. 0.811111111. PubMed
  77. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  78. Diao L, et al. 2022. iScience. 25:105511. PubMed
  79. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  80. Liu W, et al. 2021. Cell Mol Immunol. 18:2660. PubMed
  81. N'guessan P, et al. 2011. Antioxid Redox Signal. 15:1693. PubMed
  82. Wang Y, et al. 2016. Sci Rep. 6:31881. PubMed
  83. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  84. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  85. Jin X, et al. 2019. Mol Cell. 73:22:00. PubMed
  86. Tsuchiya N, et al. 2020. Cell Reports. 29(1):162-175.e9.. PubMed
  87. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  88. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  89. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  90. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  91. Tian X, et al. 2022. Front Immunol. 13:875236. PubMed
  92. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  93. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  94. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  95. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  96. Lo W, Allen D 2012. Nat Immunol. 13:880. PubMed
  97. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
  98. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  99. Morabito KM, et al. 2017. Mucosal Immunol. 0.795138889. PubMed
  100. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  101. Mauduit O, et al. 2022. Front Immunol. 13:1011125. PubMed
  102. Uchida A, et al. 2021. J Inflamm Res. 14:3089. PubMed
  103. Jia L, et al. 2022. Front Immunol. 13:897879. PubMed
  104. Li H, et al. 2021. Nat Commun. 12:2773. PubMed
  105. Zhang Z, et al. 2021. Oncoimmunology. 10:1912472. PubMed
  106. Zhang Y, et al. 2015. PLoS Pathog. 11: e1005167. PubMed
  107. Montel-Hagen A, et al. 2020. Cell Rep. 33:108320. PubMed
  108. Levine LS, et al. 2021. Immunity. 54(4):829-844.e5. PubMed
  109. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  110. Li J, et al. 2019. JCI Insight. 5. PubMed
  111. Meyer LK, et al. 2019. J Clin Invest. 130:863. PubMed
  112. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  113. Marchingo JM, et al. 2020. eLife. 9:e53725.. PubMed
  114. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  115. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  116. Dang Y, et al. 2022. Cancer Cell Int. 22:88. PubMed
  117. Wang B, et al. 2022. Nat Commun. 13:3821. PubMed
  118. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  119. Li H, et al. 2022. Theranostics. 12:6422. PubMed
  120. Burrack K, et al. 2015. PLoS Pathog. 11: e1005191. PubMed
  121. Frazier T, et al. 2018. Adipocyte. 0.41875. PubMed
  122. Naing A et al. 2019. Cell reports. 26(5):1242-1257 . PubMed
  123. Yang R, et al. 2022. Front Pharmacol. 13:774440. PubMed
  124. Hu G, et al. 2022. Cell Death Dis. 13:640. PubMed
  125. Spinner C, et al. 2015. Sci Rep. 5:16269. PubMed
  126. Qi T, et al. 2020. Cell Rep. 33:108452. PubMed
  127. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  128. Zhang W, et al. 2019. Oncol Lett. 17:815. PubMed
  129. Lee CG, et al. 2019. JCI Insight. 4:5. PubMed
  130. Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed
  131. Paul S, et al. 2018. Appl Microbiol Biotechnol. 102:8895. PubMed
  132. Hu Q, et al. 2018. Nat Biomed Eng. 0.660416667. PubMed
  133. Wang Y, et al. 2021. Front Immunol. 12:654463. PubMed
  134. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
  135. Sá da Bandeira D, et al. 2022. Cell Rep. 40:111114. PubMed
  136. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  137. Yang H, et al. 2022. Nutrients. 14:. PubMed
  138. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  139. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
  140. Burrack K, et al. 2015. J Immunol. 194:678. PubMed
  141. Parhi L, et al. 2020. Nat Commun. 2.721527778. PubMed
  142. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  143. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
  144. van Montfoort N, et al. 2018. Cell. 175:1744. PubMed
  145. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  146. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  147. James OJ, et al. 2021. Nat Commun. 12:4290. PubMed
  148. Zhao X, et al. 2013. Int Immunopharmacol. 17:793. PubMed
  149. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  150. Schuldt N, et al. 2015. PLoS One. 10: 0145762. PubMed
  151. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
  152. Guo C, et al. 2017. Methods Mol Biol. 1709:345. PubMed
  153. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  154. Loh Z, et al. 2020. PLOS Pathogens. 16(7):e1008651. PubMed
  155. Liang J, et al. 2020. Sci Adv. 6:eabc3646. PubMed
  156. Cho K, et al. 2021. iScience. 24:103117. PubMed
  157. Sun C, et al. 2022. J Adv Res. 35:71. PubMed
  158. Monaghan KL, et al. 2020. J Vis Exp. . PubMed
  159. Chou T, et al. 2016. Nat Commun. 7:11904. PubMed
  160. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  161. Manrique-Rincón A, et al. 2017. Front Immunol. 10.3389/fimmu.2017.01150. PubMed
  162. Chan WF, et al. 2022. Nat Commun. 13:5582. PubMed
  163. Moutuou MM, et al. 2020. Methods Mol Biol. 2111:267. PubMed
  164. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  165. Anderson AE, et al. 2022. NPJ Regen Med. 7:6. PubMed
  166. Lin J, et al. 2021. Nat Commun. 12:5321. PubMed
  167. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  168. Kmieciak M, et al. 2011. J Vis Exp. 47: 2381. PubMed
  169. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  170. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  171. Echevarría-Vargas IM, et al. 2018. EMBO Mol Med. 10:e8446. PubMed
  172. Subramanian K, et al. 2019. Nat Microbiol. 4:62. PubMed
  173. Watson MJ, et al. 2021. Nature. 591:645. PubMed
  174. Wu S, et al. 2021. Nat Cancer. 2:189. PubMed
  175. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  176. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  177. Han Y, et al. 2022. Int J Biol Sci. 18:5653. PubMed
  178. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  179. Liu Y, et al. 2020. Oncol Lett. 2369:20. PubMed
  180. Li J, et al. 2020. FASEB J. 34:3091. PubMed
  181. Cai Z, et al. 2020. Cell Rep. 31:107816. PubMed
  182. Rodriguez-Sosa M, et al. 2004. Infect Immun. 72:4552. PubMed
  183. Kamata T, et al. 2020. Cell Reports. 31(12):107802. PubMed
  184. Wong YC, et al. 2019. J Virol. 93:e01154-19. PubMed
  185. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  186. Zhang J, et al. 2018. Nature. 553:91. PubMed
  187. Li Z, et al. 2022. Nat Commun. 13:6321. PubMed
  188. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  189. Dong M, et al. 2022. J Immunother Cancer. 10:. PubMed
  190. Shen DD, et al. 2022. Mol Cancer. 21:75. PubMed
  191. Zhu J, et al. 2021. Cancer Cell Int. 21:529. PubMed
  192. Baranwal G, et al. 2021. Physiol Rep. 9:e15094. PubMed
  193. Bristow CL, et al. 2021. Front Oncol. 11:739080. PubMed
  194. Li J, et al. 2020. Development. :. PubMed
  195. Pai M, et al. 2016. JPEN J Parenter Enteral Nutr. 40: 383 - 391. PubMed
  196. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  197. Onai N, et al. 2020. Int J Mol Sci. :22. PubMed
  198. Xia Y, et al. 2018. Cell. 175:1059. PubMed
  199. Eisemann T, et al. 2019. Front Oncol. 9:187. PubMed
  200. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  201. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  202. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  203. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  204. Ene CI, et al. 2020. Neuro Oncol. 639:22. PubMed
  205. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  206. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  207. Flesch I, et al. 2015. J Immunol. 195: 2263-2272. PubMed
  208. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  209. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  210. Koide S, et al. 2022. iScience. 25:103603. PubMed
  211. Kline JM, et al. 2021. J Biol Chem. :100373. PubMed
  212. Yang Z, et al. 2021. Nat Commun. 12:4299. PubMed
  213. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  214. Zhu E, et al. 2014. J Immunol. 192:5599. PubMed
  215. Wu Y, et al. 2015. J Immunol. 195: 2612-2623. PubMed
  216. Jia H, et al. 2018. Int J Oncol. 53:949. PubMed
  217. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  218. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  219. Rodríguez L, et al. 2021. Biomolecules. 11: . PubMed
  220. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  221. Sun F, et al. 2022. Cell Death Dis. 13:181. PubMed
  222. Wu G, et al. 2021. Nat Cancer. 2:1170. PubMed
  223. Yang N, et al. 2022. Nat Commun. 13:2336. PubMed
  224. Schnoegl D, et al. 2022. Front Immunol. 13:909270. PubMed
  225. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  226. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  227. Aguilera TA, et al. 2020. Clin Cancer Res. 26:2972. PubMed
  228. LeBlanc P, et al. 2014. J Biol Chem. 289:7777. PubMed
  229. Yamashita M, et al. 2019. Cell Stem Cell. 25:357. PubMed
  230. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  231. Skirecki T, et al. 2020. JCI Insight. 5:. PubMed
  232. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  233. Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed
  234. Lin J, et al. 2021. Cancer Immunol Res. 9:1413. PubMed
  235. Chavez JS, et al. 2022. Cells. 11:. PubMed
  236. Wang X, et al. 2022. Elife. 11:. PubMed
  237. Wang F, et al. 2021. Neoplasia. 23:281. PubMed
  238. Wang X, et al. 2021. Theranostics. 11:209. PubMed
  239. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  240. Kang YA, et al. 2020. J Exp Med. 217:00:00. PubMed
  241. Tran S, et al. 2020. Immunity. 53(3):627-640.e5. PubMed
  242. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  243. Ren D, et al. 2020. Am J Cancer Res. 2851:10. PubMed
  244. Zeng A, et al. 2020. Oncol Rep. . PubMed
  245. Radulovic V, et al. 2020. Cell Reports. 27(10):2826-2836.e5.. PubMed
  246. Chen R, et al. 2021. Front Oncol. 11:743050. PubMed
  247. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  248. Zhang M, et al. 2022. iScience. 25:104490. PubMed
  249. Gawish R, et al. 2022. Elife. 11:. PubMed
  250. Lv K, et al. 2021. Cell Stem Cell. 28(7):1275-1290.e9. PubMed
  251. Yang E, et al. 2015. Acta Biochim Biophys Sin. 47: 588-596. PubMed
  252. Zhou T, et al. 2018. Mol Med Rep. 17:4883. PubMed
  253. Lee YT, et al. 2018. PLoS One. 13:e0190868. PubMed
  254. Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
  255. Xu Z, et al. 2022. Cell Death Dis. 13:502. PubMed
  256. Pastor Arroyo EM, et al. 2022. Clin Sci (Lond). 136:557. PubMed
  257. Shi GN, et al. 2021. Ther Adv Med Oncol. 13:1758835920987056. PubMed
RRID
AB_312746 (BioLegend Cat. No. 100707)
AB_312747 (BioLegend Cat. No. 100708)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD8alpha
Specificity Alt (DOES NOT SHOW ON TDS):
CD8a
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV™ 395 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01.21.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account